Immunolabeling for Neurodegenerative Diseases: Deciphering the Molecular Pathology of Alzheimer’s

Featured Speakers: Li-Huei Tsai, PhD (Broad Institute MIT), and Raphael Rozenfeld, PhD (CST)
ℹ️ Explore the Hallmarks of Neurodegeneration:https://cst-science.com/48hzpd
⬇️ Expand “Show More” to view abstract and table of contents

Alzheimer’s disease presents stereotypical pathological features including the abundance of amyloid deposition and tauopathy. Affected brain regions also exhibit reactive astrogliosis, neuroinflammatory responses, and vascular pathology. Neuronal and synaptic loss is also evident. Various mouse lines have been created to investigate Alzheimer’s disease and most of the models exhibit a subset of the defining pathological features of the disease. In this webinar the speaker will discuss the use of Alzheimer’s disease transgenic mouse models to evaluate pathological features by both traditional immunohistochemistry and new tissue processing methods that enable whole- brain imaging. These immunolabeling methods further the investigation of molecular and neural circuit mechanisms of Alzheimer’s disease.

About CST®: Cell Signaling Technology (CST) is a private, family-owned company, founded by scientists and dedicated to providing high-quality research tools to the biomedical research community. Our employees operate worldwide from our U.S. headquarters in Massachusetts, and our offices in the Netherlands, China, and Japan. https://cellsignal.com/about

All trademarks are the property of their respective owners. For the most up-to-date trademark information, please visit https://www.cellsignal.com/trademarks

Видео Immunolabeling for Neurodegenerative Diseases: Deciphering the Molecular Pathology of Alzheimer’s канала Cell Signaling Technology, Inc.